DeepMed Research

Acamprosate

Generic Name: Acamprosate

Brand Names: Campral

Drug Type: Small Molecule

Chemical Formula: C_₅H_₁₁NO_₄S

CAS Number: 77337-76-9

Unique Ingredient Identifier: N4K14YGM3J

Background: Alcohol use disorder is responsible for a large worldwide burden of morbidity, premature mortality, and economic consequences resulting from accidents, violence, incarceration, decreased productivity, and increased healthcare spending.

Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence. It is a structural analogue of the neurotransmitter γ-aminobutyric acid (GABA). Acamprosate is the first medication specifically formulated for the maintenance of alcohol abstinence in ethanol-dependent patients after alcohol detoxification, unlike naltrexone and disulfiram. It was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.

Indication: Acamprosate is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. It is also indicated for the maintenance of alcohol abstinence in patients who have undergone alcohol detoxification. This drug should be used with a psychosocial support program providing adequate support.

Associated Conditions: Alcohol Abstinence, Alcohol Dependency

Clinical Trials

Safety of Acamprosate in Treating Alcohol Use Disorder in the Post Liver Transplant Populations

Phase 2

Completed

Conditions: Liver Transplant; Complications
Alcohol Use Disorder

Interventions: Drug: Acamprosate

First Posted Date: 2024-06-24

Last Posted Date: 2024-06-27

Lead Sponsor: University of Southern California

Target Recruit Count: 30

Registration Number: NCT06471686

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

Acamprosate and Methazolamide for Essential Tremor

Phase 2

Withdrawn

Conditions: Essential Tremor

Interventions: Drug: Acamprosate
Drug: Placebo
Drug: Methazolamide

First Posted Date: 2024-03-15

Last Posted Date: 2024-03-15

Lead Sponsor: Henry Ford Health System

Registration Number: NCT06312800

Locations: 🇺🇸
Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

Phase 4

Recruiting

Conditions: Alcohol Use Disorder

Interventions: Drug: Acamprosate calcium
Other: Placebo

First Posted Date: 2024-02-21

Last Posted Date: 2025-05-13

Lead Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Target Recruit Count: 48

Registration Number: NCT06269627

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Vortioxetine for Treatment of Depressive Mood and Alcohol Use

Phase 2

Conditions: Alcoholism
Depressive Disorder, Major

Interventions: Drug: Vortioxetine
Drug: Acamprosate

First Posted Date: 2020-08-05

Last Posted Date: 2020-08-05

Lead Sponsor: Hanyang University Seoul Hospital

Target Recruit Count: 128

Registration Number: NCT04498897

Locations: 🇰🇷
Hanyang USH, Seoul, Korea, Republic of

Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome

Phase 4

Completed

Conditions: Alcohol Use Disorder

Interventions: Other: Placebo
Drug: Acamprosate

First Posted Date: 2019-01-28

Last Posted Date: 2024-12-17

Lead Sponsor: Mayo Clinic

Target Recruit Count: 288

Registration Number: NCT03818191

Locations: 🇺🇸
Hazelden Betty Ford Foundation, Newberg, Oregon, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Investigation of the Efficacy of Acamprosate and Calcium in Comparison to Placebo as Validation of a Behavioural Test for Alcohol Dependence

Phase 3

Completed

Conditions: Alcoholism

Interventions: Drug: Acamprosate Calcium
Drug: Calcium Carbonate
Drug: Placebo
Drug: Placebo lead in

First Posted Date: 2018-08-17

Last Posted Date: 2024-05-29

Lead Sponsor: Technische Universität Dresden

Target Recruit Count: 82

Registration Number: NCT03634917

Locations: 🇩🇪
Klinik und Poliklinik für Psychiatrie und Psychotherapie; Technische Universität Dresden, Dresden, Sachsen, Germany

Neurophysiological and Acute Pharmacological Studies in FXS Patients

Early Phase 1

Completed

Conditions: Fragile X Syndrome

Interventions: Drug: Acamprosate
Drug: Lovastatin
Drug: Minocycline
Drug: Placebo
Drug: Baclofen

First Posted Date: 2016-12-20

Last Posted Date: 2021-11-26

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 29

Registration Number: NCT02998151

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder

Phase 2

Withdrawn

Conditions: Post-Traumatic Stress Disorders
Posttraumatic Stress Disorders
Stress Disorders, Post-Traumatic
Post-Traumatic Stress Disorders, Combat-related

Interventions: Drug: SNC-102 sustained release tablet

First Posted Date: 2015-03-10

Last Posted Date: 2016-04-18

Lead Sponsor: Synchroneuron Inc.

Registration Number: NCT02384369

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3

Terminated

Conditions: Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders

Interventions: Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium

First Posted Date: 2015-03-02

Last Posted Date: 2018-02-28

Lead Sponsor: Hannover Medical School

Target Recruit Count: 407

Registration Number: NCT02374567

Locations: 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪
Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪
Hannover Medical School, Hannover, Germany

and more 2 locations

A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome

Phase 2

Withdrawn

Conditions: Tourette Syndrome

Interventions: Drug: SNC-102 sustained release tablet

First Posted Date: 2014-08-15

Last Posted Date: 2021-04-13

Lead Sponsor: Synchroneuron Inc.

Registration Number: NCT02217007

Locations: 🇺🇸
North Shore University Hospital, Dept. of Psychiatry, Manhasset, New York, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy